Truly Novel RA Drug Passes Mid-Stage Test

(MedPage Today) -- Combining the Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) with an investigational oral drug targeting a different type of kinase enzyme was more effective against rheumatoid arthritis (RA) than tofacitinib alone in a phase...